Monopar Therapeutics Inc. Share Price
MNPRMonopar Therapeutics Inc. Stock Performance
Open $58.02 | Prev. Close $59.26 | Circuit Range N/A |
Day Range $56.49 - $58.02 | Year Range $26.05 - $103.77 | Volume 1,221 |
Average Traded $56.99 |
Monopar Therapeutics Inc. Share Price Chart
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Monopar Therapeutics Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
18-Mar-26 | $55.73 | $58.66 | -4.45% |
17-Mar-26 | $62.19 | $61.40 | -0.16% |
16-Mar-26 | $60.98 | $61.50 | +1.54% |
13-Mar-26 | $60.17 | $60.57 | +4.79% |
12-Mar-26 | $54.96 | $57.80 | +1.83% |
11-Mar-26 | $57.55 | $56.76 | -3.37% |
10-Mar-26 | $58.98 | $58.74 | +0.98% |